ArticlePloS one2026
Mutations in the N-glycan branching enzyme MGAT1 promote invasiveness and EGF-stimulated proliferation and adhesion in neuroblastoma cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Attachment and modification of N-glycans to proteins have been linked to the promotion of cancer, and specifically, more recent investigations have supported the involvement of less processed N-glycans. Herein, we investigated how reduced activity of N-acetylglucosaminyltransferase-I (GnT-I, MGAT1) influences aberrant cellular properties and epidermal growth factor receptor (EGFR) signaling in human NB cells. CRISPR/Cas9 technology was used to introduce mutations into MGAT1 in the parental BE(2)-M17 cell line, generating the MGAT1 mutant cell lines, Trunc and Δ45. Lectin binding studies showed increased oligomannose type N-glycans accompanied by decreased hybrid and complex types of N-glycans in both MGAT1 mutant cell lines relative to BE(2)-M17, and the level of oligomannose type N-glycans were reversed in the mutant cells by ectopic expression of GnT-I. Reduced GnT-I activity increased the percentage of S-type cells and decreased the percentage of N-type cells. Anchorage-independent cell growth was reduced in both MGAT1 mutant cell lines, and cell proliferation was slower at sub-confluency. Unexpectedly, cell proliferation rates were increased in confluent and over-confluent cell cultures, as they were in three-dimensional cell spheroids, in the MGAT1 mutant lines compared to the parental cell line. Trunc and Δ45 cells were less sensitive to mechanical dissociation and retained larger intact cell clusters, supporting that increased oligomannose N-glycans strengthen cell-cell adhesion. MGAT1 mutant cell lines were also more invasive than BE(2)-M17. Following EGF stimulation, Trunc and Δ45 cells had increased levels of P-EGFR (Y1068), along with enhanced EGF-stimulated cell proliferation and cell-cell adhesion, whereas the parental cell line was relatively unresponsive. Taken together, these results show that decreased GnT-I activity imparts NB cells to perpetually proliferate at high cell densities. Furthermore, increased oligomannose N-glycans strengthened cell-cell contacts, promoted cell invasiveness, and enhanced EGF-stimulated proliferation, supporting a novel role of oligomannose N-glycans in NB progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.